• Corpus ID: 27758279

fficacy and Safety of Transcranial Magnetic timulation in the Acute Treatment of Major epression : A Multisite Randomized Controlled Trial

  title={fficacy and Safety of Transcranial Magnetic timulation in the Acute Treatment of Major epression : A Multisite Randomized Controlled Trial},
  author={ohn P. O’Reardon and Hugh Brent Solvason and Philip G. Janicak and Shirlene M. Sampson and Keith E. Isenberg and iad Nahas and William M. McDonald and David H Avery and Paul B. Fitzgerald and Colleen K. Loo and Mark A Demitrack and Shefin Sam George and Harold A. Sackeim},
ethods: In a double-blind, multisite study, 301 medication-free patients with major depression who had not benefited from prior reatment were randomized to active (n 155) or sham TMS (n 146) conditions. Sessions were conducted five times per week with TMS t 10 pulses/sec, 120% of motor threshold, 3000 pulses/session, for 4 – 6 weeks. Primary outcome was the symptom score change as assessed t week 4 with the Montgomery–Asberg Depression Rating Scale (MADRS). Secondary outcomes included changes… 

Tables from this paper

Transcranial magnetic stimulation during pregnancy
High-frequency repetitive transcranial magnetic stimulation was well tolerated and found to be statistically and clinically effective in pregnant patients with treatment-resistant depression and contributed to the existing evidence of the antidepressant effect of rTMS in the treatment of depression in pregnancy.
Equivalent beneficial effects of unilateral and bilateral prefrontal cortex transcranial magnetic stimulation in a large randomized trial in treatment-resistant major depression.
The results of this study do not support superior efficacy of bilateral rTMS and instead suggest that other approaches should be explored to increase treatment efficacy.
Repetitive transcranial magnetic stimulation in Malta : a revolutionary therapy for psychiatric and neurological disorders
Repetitive transcranial magnetic stimulation (rTMS) is a safe, painless, effective, natural, evidence-based treatment for patients suffering from severe unipolar affective disorder/depression who are treatment resistant and/ or treatment intolerant.
Heart rate variability is a trait marker of major depressive disorder: evidence from the sertraline vs. electric current therapy to treat depression clinical study.
The findings confirmed that patients displayed decreased HRV relative to controls and HRV scores did not change following treatment with either a non-pharmacological (tDCS) or pharmacological (sertraline) intervention, nor did HRV increase with clinical response to treatment.
Default Model Network Mechanism in Current and Remitted Depression
The lower DMN function connectivity in frontal, temporal, and parietal cortexes in remitted depression suggests a potential over-compensation (inhibition) mechanism behind the remission of depression.


A Controlled Study of Repetitive Transcranial Magnetic Stimulation in Medication-Resistant Major Depression
Transcranial magnetic stimulation can produce statistically and clinically significant antidepressant effects in patients with medication-resistant major depression.
Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression.
Repetitive transcranial magnetic stimulation did not provide significantly greater improvement than did sham treatment and a 4-week course of rTMS, as administered in this study, was safe.
Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial.
Treatment with LFR-TMS may prove to be an appropriate initial repetitive TMS strategy in depression taking into account safety, tolerability, and efficacy considerations.
Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a double-blind controlled study.
Evidence is provided for the short-term efficacy of slow repetitive TMS in patients with recurrent major depression as compared with electroconvulsive therapy as well as the long-term outcome of this treatment in major depression and possibly other psychiatric disorders.
Tolerability and Safety of High Daily Doses of Repetitive Transcranial Magnetic Stimulation in Healthy Young Men
This study examined whether high doses of rTMS within a day or over a week would produce significant side effects and exposed healthy men to 12,960 magnetic pulses a day for up to 3 days in 1 week, which is likely one of the largest exposures of TMS to date.
Vagus Nerve Stimulation (VNS™) for Treatment-Resistant Depression: Efficacy, Side Effects, and Predictors of Outcome
VNS appears to be most effective in patients with low to moderate, but not extreme, antidepressant resistance, and evidence concerning VNS' long-term therapeutic benefits and tolerability will be critical in determining its role in treatment-resistant depression.
Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis.
Transcranial magnetic stimulation (TMS) is a technology that allows for non-invasive modulation of the excitability and function of discrete brain cortical areas. TMS uses alternating magnetic fields
Efficacy of rapid-rate repetitive transcranial magnetic stimulation in the treatment of depression: a systematic review and meta-analysis.
  • J. Couturier
  • Psychology, Medicine
    Journal of psychiatry & neuroscience : JPN
  • 2005
This meta-analysis suggests that rapid-rate rTMS is no different from sham treatment in major depression; however, the power within these studies to detect a difference was generally low.
Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression
It is suggested that rTMS of the left dorsolateral prefrontal cortex might become a safe, non-convulsive alternative to electroconvulsive treatment in depression.
Effects of a 2- to 4-week course of repetitive transcranial magnetic stimulation (rTMS) on neuropsychologic functioning, electroencephalogram, and auditory threshold in depressed patients
Overall, rTMS for up to 4 weeks is safe, but individual results suggest caution and the need for further investigation of the safety of several weeks of rT MS, and there were trends for improvement in neuropsychologic performance.